SCHEMBL1496907

SCHEMBL1496907

COc1cccc(CNC(=O)NC(CCN(C)C)c2ccc(C(=O)Nc3cscc3NC(=O)OC(C)(C)C)nc2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 9/20 0.45
ALDH1A1 P00352 3/20 0.39
ROCK2 O75116 4/20 0.38
ROCK1 Q13464 3/20 0.38
ATG4B Q9Y4P1 1/20 0.38
ANPEP P15144 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
GFER P55789 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PRKACA P17612 1/20 0.37
GRK5 P34947 1/20 0.37
PRKX P51817 1/20 0.37
PRKCQ Q04759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497003 0.91 UTS2R (0.44) UTS2RALDH1A1
SCHEMBL1497033 0.91 UTS2R (0.44) UTS2RALDH1A1ROCK2ROCK1ATG4B
SCHEMBL11899970 0.89 UTS2R (0.59) UTS2RALDH1A1ROCK2ROCK1
SCHEMBL1497068 0.88 UTS2R (0.47) UTS2RALDH1A1ROCK2ROCK1ATG4B
SCHEMBL1496976 0.88 UTS2R (0.45) UTS2RALDH1A1KMT2AHSD17B10
SCHEMBL1497113 0.87 UTS2R (0.45) UTS2RROCK2
SCHEMBL1497075 0.86 UTS2R (0.44) UTS2RMEN1GAAKMT2A
SCHEMBL10476441 0.86 UTS2R (0.41) UTS2RALDH1A1ROCK2ROCK1ANPEP
SCHEMBL1496849 0.86 UTS2R (0.44) UTS2RMEN1KMT2A
SCHEMBL10476443 0.85 UTS2R (0.38) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 UTS2R 195/4885ALDH1A1 1240/4885ROCK2 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.